Crossmark

Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion

Crossref DOI link: https://doi.org/10.1007/s11523-026-01242-z

Published Online: 2026-09-12

Published Print: 2026-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Iams, Wade T.

Florez, Narjust
Funding

Funding for this research was provided by:

EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA
License Information

Text and Data Mining valid from 2026-09-01

Version of Record valid from 2026-09-12
More Information

Article History

Received: 22 December 2025

Accepted: 15 July 2026

First Online: 12 September 2026

Declarations

Competing interests: Wade T Iams: Consulting or advisory role: Sanofi, Elevation Oncology, AstraZeneca, NovoCure, Catalyst, Janssen, Takeda, Bristol Myers Squibb, Mirati, Chardan Consulting, Curio Science, Defined Health, G1 Therapeutics, Genentech, Jazz Pharmaceuticals, Outcomes Insights, and EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA. Narjust Florez: Research funding from Genentech, AstraZeneca, Daiichi Sankyo, Johnson and Johnson, American Society of Clinical Oncology, Lungevity Foundation, and International Association for the Study of Lung Cancer and consulting fees or honoraria from: AstraZeneca, Daiichi Sankyo, Genentech, Bristol Myers Squibb, Jazz Pharmaceuticals, Johnson and Johnson, Novocure, Pfizer, Sanofi, MSD, Takeda, Catalyst Pharmaceuticals, and Regeneron.

Ethics approval, consent to participate, consent to publish: Not applicable.

Data availability, code availability: Not applicable.

Authors’ contributions: Narjust Florez and Wade Iams: validation, writing—review and editing, and visualization.

Document is current

Any future updates will be listed below